Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate Mofetil in Rosai-Dorfman Disease
NCT05284942Phase 4Unknown
- Sponsor
- Tongji Hospital
- Start
- Oct 2011
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate mofetil in Rosai-Dorfman disease (RDD), sponsored by Tongji Hospital. Primary endpoint: Autoimmune Bullous Disease Quality of Life at 108 weeks. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
Rosai-Dorfman disease (RDD)
Beyond the preview
Go deeper on NCT05284942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284942.